View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
February 26, 2020updated 22 Nov 2021 8:05am

Vir Biotechnology and WuXi Biologics team up for Covid-19 therapies

Vir Biotechnology has partnered with WuXi Biologics to develop and produce human monoclonal antibodies to treat Covid-19 caused by the novel coronavirus.


Visit our Covid-19 microsite for the latest coronavirus news, analysis and updates

Free Whitepaper
img

What is the impact of China’s Zero-COVID lockdowns on economic activity, consumer goods and the foodservice industry?

While wanting to protect the country from being overwhelmed by Omicron, China’s adherence to a Zero-COVID policy is resulting in a significant economic downturn. COVID outbreaks in Shanghai, Beijing and many other Chinese cities will impact 2022’s economic growth as consumers and businesses experience rolling lockdowns, leading to a slowdown in domestic and international supply chains. China’s Zero-COVID policy is having a demonstrable impact on consumer-facing industries. Access GlobalData’s new whitepaper, China in 2022: the impact of China’s Zero-COVID lockdowns on economic activity, consumer goods and the foodservice industry, to examine the current situation in Shanghai and other cities in China, to better understand the worst-affected industry sectors, foodservice in particular, and to explore potential growth opportunities as China recovers. The white paper covers:
  • Which multinational companies have been affected?
  • What is the effect of lockdowns on foodservice?
  • What is the effect of lockdowns on Chinese ports?
  • Spotlight on Shanghai: what is the situation there?
  • How have Chinese consumers reacted?
  • How might the Chinese government react?
  • What are the potential growth opportunities?
by GlobalData
Enter your details here to receive your free Whitepaper.

Follow the latest updates of the outbreak on our timeline.

Vir Biotechnology has partnered with WuXi Biologics to develop and produce human monoclonal antibodies to treat Covid-19 caused by the novel coronavirus.

The partnership, which covers Vir’s antibodies, will involve clinical development, manufacturing and commercialisation.

WuXi Biologics will be responsible for cell-line development, process and formulation development and early production for clinical development.

If the antibodies obtain regulatory approvals, WuXi Biologics holds the commercialisation rights in Greater China, while Vir has the commercialisation rights in all the remaining global markets.

WuXi Biologics Chris Chen said: “Both WuXi Biologics and Vir felt the great urgency to develop antibodies to treat global patients provided they work in the clinic.

“Our state-of-the-art technology platform and robust global-quality supply network make us uniquely qualified in expediting the development and manufacturing of these potential treatments.”

Vir discovered multiple monoclonal antibodies that can attach to SARS-CoV-2, obtained from people who contracted and then recovered from SARS infection.

Currently, the company is exploring whether its antibodies or other antibodies identified possess effectiveness for treatment or prophylaxis against the novel coronavirus.

Vir Biotechnology CEO George Scangos said: “In the event that we are in a position to develop an antibody therapy, our agreement with WuXi Biologics enables us to accelerate advancement against this global threat.”

Last month, Vir said that the company is using different platforms to determine if its previously identified mAbs against coronavirus can bind and neutralise the virus.

The company is using its antibody technology to isolate antibodies specific for SARS-CoV-2.


See all Coronavirus vaccines and drugs in the pipeline

 

Related Companies

Free Whitepaper
img

What is the impact of China’s Zero-COVID lockdowns on economic activity, consumer goods and the foodservice industry?

While wanting to protect the country from being overwhelmed by Omicron, China’s adherence to a Zero-COVID policy is resulting in a significant economic downturn. COVID outbreaks in Shanghai, Beijing and many other Chinese cities will impact 2022’s economic growth as consumers and businesses experience rolling lockdowns, leading to a slowdown in domestic and international supply chains. China’s Zero-COVID policy is having a demonstrable impact on consumer-facing industries. Access GlobalData’s new whitepaper, China in 2022: the impact of China’s Zero-COVID lockdowns on economic activity, consumer goods and the foodservice industry, to examine the current situation in Shanghai and other cities in China, to better understand the worst-affected industry sectors, foodservice in particular, and to explore potential growth opportunities as China recovers. The white paper covers:
  • Which multinational companies have been affected?
  • What is the effect of lockdowns on foodservice?
  • What is the effect of lockdowns on Chinese ports?
  • Spotlight on Shanghai: what is the situation there?
  • How have Chinese consumers reacted?
  • How might the Chinese government react?
  • What are the potential growth opportunities?
by GlobalData
Enter your details here to receive your free Whitepaper.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Pharmaceutical Technology